Two high-flying ASX shares: One upgraded, one downgraded

One of these high-flying shares could keep rising and one could fall.

| More on:
A businesswoman on the phone is shocked as she looks at her watch, she's running out of time.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two ASX shares that have made their shareholders smile this year are DroneShield Ltd (ASX: DRO) and Telix Pharmaceuticals Ltd (ASX: TLX).

Since the start of the year, their shares have risen by approximately 120% and 50%, respectively. As a comparison, the Australian share market is up around 0.5% over the same period.

However, one leading broker believes that one of these high-flying ASX shares could have peaked for the time being. This has led to its analysts downgrading its shares to a hold rating.

The good news for the other share is that its analysts have gone the other way with it. Despite its very strong gains, the broker has upgraded it to a buy rating from hold this week.

Which ASX shares have been downgraded?

According to a note out of Bell Potter, its analysts have downgraded Telix Pharmaceuticals' shares to a hold rating with a $14.50 price target. This implies a potential downside of 5% from its current share price of $15.24.

While the broker is a big fan of the radiopharmaceuticals company, it feels that its valuation is full. Particularly given that there are significant clinical risks on the horizon. Commenting on the downgrade, its analysts said:

The short term outlook for revenue growth from the diagnostic assets remains attractive, nevertheless the major inflection points for TLX591 in the treatment of prostate cancer are close and carry significant clinical risk. We expect a readout on the important efficacy measure of progression free survival within the next 2 to 3 months. A poor clinical readout has the potential to materially impact the share price and accordingly we downgrade from Buy to Hold on the basis of valuation, noting this is the first recommendation downgrade since our initiation coverage in 2021. PT remains $14.50.

DroneShield upgraded

On the same day, the broker upgraded this counter drone technology company's shares to a buy rating with a $1.00 price target. Based on the current DroneShield share price of 83 cents, this implies a potential upside of 20% for investors.

The broker made the move following a pullback in its share price in response to a recent capital raising. It feels this funding leaves DroneShield well-positioned to capture the increasing demand for its technology. It explains:

DroneShield is now well placed to capitalise on the growing demand for C-UAS solutions in response to current global tensions and the evolution of modern warfare. Our forecasts likely remain conservative relative to the current sales pipeline, however the risk of government delay remains prevalent in contracts of this nature. With the SP now trading near the issue price, we upgrade our recommendation to BUY.

Should you invest $1,000 in Altium right now?

Before you buy Altium shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Altium wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Suncorp share price Businessman cheering and smiling on smartphone
Growth Shares

3 ASX 200 shares for smart investors to buy

Analysts think these shares could be smart buys this month. Let's find out why.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Growth Shares

Looking for ASX growth shares? I rate these 2 as buys in May

These ASX investments have an exciting future. Here’s why.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Growth Shares

The best ASX growth stocks for smart investors to buy with $5,000

Analysts are bullish on these shares. Let's find out why.

Read more »

Happy young couple saving money in piggy bank.
Growth Shares

Where to invest $2,500 into ASX 200 shares today

Analysts think these shares could be top buys for investors with money to invest.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Growth Shares

3 excellent ASX shares to buy for your SMSF

Analysts think these shares could be top picks for SMSF investors. Let's find out why.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Growth Shares

2 ASX growth shares to supercharge your portfolio

Analysts think these shares could be in the buy zone for growth investors right now.

Read more »

A group of people gathered around a laptop computer with various expressions of interest, concern and surprise on their faces. All are wearing glasses.
Growth Shares

Turn $300 into significant wealth: 3 explosive ASX opportunities for Aussie investors

Analysts think these shares could be great picks for growth focused investors.

Read more »

A man looking at his laptop and thinking.
Growth Shares

What I'd buy with $2,000 on the ASX right now

Here are three options for investors to look at this month.

Read more »